研究报告 |
|
|
|
|
重组人胰高血糖素样肽-1类似物的分离纯化和鉴定 |
高相雷, 林树珊, 龚庆伟, 潘兰, 马利, 冯艳, 林小鹊, 曾剑, 李文佳, 陈小锋, 陈英 |
广东东阳光药业有限公司 东莞 523000 |
|
Purification and Characterization of Recombinant Human Glucagon-like Peptide-1 Analogue |
GAO Xiang-lei, LIN Shu-shan, GONG Qing-wei, PAN Lan, MA Li, FENG Yan, LIN Xiao-que, ZENG Jian, LI Wen-jia, CHEN Xiao-feng, CHEN Ying |
Guangdong HEC Pharmaceutical Co., Ltd. Dongguan 523000, China |
引用本文:
高相雷, 林树珊, 龚庆伟, 潘兰, 马利, 冯艳, 林小鹊, 曾剑, 李文佳, 陈小锋, 陈英. 重组人胰高血糖素样肽-1类似物的分离纯化和鉴定[J]. 中国生物工程杂志, 2016, 36(12): 15-20.
GAO Xiang-lei, LIN Shu-shan, GONG Qing-wei, PAN Lan, MA Li, FENG Yan, LIN Xiao-que, ZENG Jian, LI Wen-jia, CHEN Xiao-feng, CHEN Ying. Purification and Characterization of Recombinant Human Glucagon-like Peptide-1 Analogue. China Biotechnology, 2016, 36(12): 15-20.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/DOI:10.13523/j.cb.20161203
或
https://manu60.magtech.com.cn/biotech/CN/Y2016/V36/I12/15
|
[1] 翁建平. 人胰高血糖素样肽-1受体激动剂的作用机制. 中国老年学杂志,2015, 20:5981-5983. Weng J P, The mechanism of human glucagon like peptide -1 receptor agonists. Chinese Journal of Gerontology, 2015, 20:5981-5983.
[2] 郑少茹,张洁,王战建. 胰高血糖素样肽-1改善胰岛功能的研究进展. 疑难病杂志,2016, 05:542-545. Zheng S R, Zhang J, Wang Z J. Research progress of glucagon like peptide -1 in improving islet function. Chinese Journal of Difficult and Complicated Cases, 2016, 05:542-545.
[3] 朱大龙,杨文英. 人胰高血糖素样肽-1类似物的合理应用. 临床药物治疗杂志,2013, 01:1-5. Zhu D L, Yang W Y. Application of glucagon-like peptide-1 analogue. Clinical Medication Journal, 2013, 01:1-5.
[4] Li C, Huan Y, Shen N, et al. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect. Biochemical & Biophysical Research Communications, 2010, 400(4):563-568.
[5] Bo A. GLP-1 for type 2 diabetes. Experimental Cell Research, 2011, 317(9):1239-1245.
[6] 曹筱佩,阳池娇. 人胰高血糖素样肽-1类似物的临床疗效及不良反应. 临床药物治疗杂志,2013, 01:45-48. Cao X P, Yang C J. Clinical efficacy and adverse reactions of human glucagon like peptide -1 analogues. Clinical Medication Journal, 2013, 01:45-48.
[7] 杨懿,万德友,刘蕴慧,等. 长效GLP-1-IgG2σ Fc融合蛋白的真核表达与生物活性鉴定. 生物技术通讯,2016, 02:173-177. Yang Y, Wan D Y, Liu Y H, et al. Eukaryotic expression and activity detection of GLP-1-IgG2σ Fc fusion protein. Letters in Biotechnology, 2016, 02:173-177.
[8] Holst J J. The physiology of glucagon-like peptide 1. Physiological Reviews, 2007, 87(4):1409-1439.
[9] 田雅晨,陈在余,马爱霞. 我国糖尿病用药市场产业环境分析. 现代商贸工业,2013,08:69-71. Tian Y C, Chen Z Y, Ma A X. Analysis of the industrial environment of Chinese diabetes drug market. Modern Business Trade Industry,2013,08:69-71.
[10] Bo A. Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discovery Today Therapeutic Strategies, 2004, 1(2):207-212.
[11] 祁浩,刘新利,谭永水. GLP-1毕赤酵母表达载体的构建及重组菌株的筛选. 齐鲁工业大学学报(自然科学版),2016, 02:27-30. Qi H, Liu X L, Tan Y S. Construction and screening of Pichia pastoris expression vector of recombinant strain GLP-1. Journal of Qilu University of Technology(Natural Science Edition), 2016, 02:27-30.
[12] 马雪. 重组人胰高血糖素样肽-1前药(Pro-rhGLP-1)的表达、纯化及药效学研究. 西安:第四军医大学,2010. Ma X. Expression, purification and pharmacologic properties of Pro-rhGLP-1, a prodrug of recombinant human glucagon-like peptide-1. Xian:The Fourth Military Medical University, 2010. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|